In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Tectonic Therapeutic, with a price target of $87.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight Tectonic Therapeutic’s strategic advancements and promising pipeline. The company is actively progressing its lead program with TX-45, a long-acting SC Fc-relaxin fusion protein, which is currently in a Phase 2 study for pulmonary hypertension patients with heart failure. The ongoing trials and the expected data releases in 2025 and 2026 are crucial milestones that could significantly de-risk the program and expand its market potential.
Moreover, Tectonic’s planned expansion into pulmonary hypertension associated with interstitial lung disease (PH-ILD) with TX-45 represents a strategic move into an area with limited treatment options. The potential first-in-class relaxin therapy aims to leverage its vasodilatory effects, positioning it as a promising candidate in the PH-ILD space. These developments, coupled with the company’s financial health and strategic execution, underpin the Buy rating given by Cory Jubinville, PhD.